APA (7th ed.) Citation

Sharma, P., & Jäger, D. (2016). Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The lancet. Oncology, 17(11), . https://doi.org/10.1016/S1470-2045(16)30496-X

Chicago Style (17th ed.) Citation

Sharma, Padmanee, and Dirk Jäger. "Nivolumab Monotherapy in Recurrent Metastatic Urothelial Carcinoma (CheckMate 032): A Multicentre, Open-label, Two-stage, Multi-arm, Phase 1/2 Trial." The Lancet. Oncology 17, no. 11 (2016). https://doi.org/10.1016/S1470-2045(16)30496-X.

MLA (9th ed.) Citation

Sharma, Padmanee, and Dirk Jäger. "Nivolumab Monotherapy in Recurrent Metastatic Urothelial Carcinoma (CheckMate 032): A Multicentre, Open-label, Two-stage, Multi-arm, Phase 1/2 Trial." The Lancet. Oncology, vol. 17, no. 11, 2016, https://doi.org/10.1016/S1470-2045(16)30496-X.